infectious diseases

infectious diseases

Interactive Data Dashboards

Track the HIV & TB response

Key indicators, province breakdowns and downloadable graphs.

  • XACT III: A trial asking how to take TB tests to the people

    Roughly two in five people newly ill with TB worldwide are never diagnosed. In South Africa, this amounts to about 120 000 to 160 000 people per year. A large new study called XACT III is testing ways in which more people can be diagnosed and started on TB treatment more quickly. Tiyese Jeranji reports.

    ·

  • Six ways clinics can help turn the tide on TB infection

    Six simple interventions are at the heart of how clinics can be part of turning the tide on TB infection. By following a checklist of good practice, clinics can be safer for patients and staff. However, most clinics are failing to implement enough of these measures, putting people at risk of getting TB while waiting…

    ·

  • COVID-19: Second wave was “like a tsunami”, reflects Tygerberg doctor

    Spotlight first interviewed physician and infectious diseases specialist Dr Arifa Parker in May last year as South Africa’s first wave of COVID-19 was building up. Eleven very difficult months later, Bienne Huisman checks in with Parker to hear how things are going on the frontlines at Tygerberg Hospital.

    ·

  • COVID-19 in kids: What have we learnt one year later?

    It has been over a year since the world saw the first confirmed case of COVID-19, yet the science behind the virus’ physical impact on children remains relatively unclear. Kathryn Cleary spoke to two experts in paediatrics and immunology to get an update on what we have learnt so far.

    ·

  • Tens of thousands of people with TB in SA not diagnosed, survey

    Over 150 000 people who had TB in South Africa in 2018 were not diagnosed, according to findings from South Africa’s long-awaited National Tuberculosis Prevalence Survey. One reason for this is that an unexpectedly high number of people do not show the typical TB symptoms and are never x-rayed. Amy Green reports.

    ·

  • SAHPRA decision on ivermectin shifts heavy responsibility to doctors

    In allowing section 21 applications as part of a controlled compassionate access programme, SAHPRA has essentially shifted the responsibility for deciding whether the anti-parasitic ivermectin is safe and effective enough to be used in the treatment of COVID-19 to doctors. This places an enormous responsibility on doctors, writes Adele Baleta.

    ·

  • 400 people in SA with highly drug-resistant TB to get new three-drug regimen

    Treating highly drug-resistant forms of tuberculosis can take anything from nine to 24 months and patients have to contend with various unpleasant, and sometimes dangerous, side effects. A new six-month regimen made up of just three drugs that will be offered to 400 patients in South Africa might offer a better solution for some. Tiyese…

    ·

  • Sub-clinical TB: Fascinating SA research helps push frontiers of TB science

    While likely millions of people in South Africa have latent tuberculosis (TB) infection, only between three and 10% of these people ever fall ill with TB. Cutting-edge research conducted in South Africa has now taken us a significant step closer to a test that can predict who will and who will not fall ill with…

    ·

  • Getting Gauteng’s HIV and TB response back on track

    From March to July this year, the Gauteng Department of Health recorded 57 848 TB tests – a decrease of about 30 000 tests compared to the same period last year. The province performed better with HIV testing, although the HIV response has faltered in other areas. Melissa Javan makes sense of the province’s numbers and speaks…

    ·

  • Some TB patients still required to take pills in front of witnesses

    Some tuberculosis patients in South Africa are still required to take their pills in front of a healthcare worker or family member. Is this a justified means of ensuring people take their medicine, or is it an invasion of personal autonomy? Elri Voigt asked local TB experts.

    ·